Remdesivir Experimental Antiviral for Coronavirus (COVID 19) .pdf
Original filename: Remdesivir Experimental Antiviral for Coronavirus (COVID-19).pdf
This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 03/04/2020 at 10:03, from IP address 103.121.x.x.
The current document download page has been viewed 36 times.
File size: 67 KB (2 pages).
Privacy: public file
Download original PDF file
Remdesivir: Experimental Antiviral for
What Is Remdesivir (RDV)?
Remdesivir (RDV, GS-5734) is a new antiviral drug in the nucleotide analog
category. The drug was developed by Gilead, and the earliest development of
the drug was against Ebola virus (EBOV). And it is not currently approved
globally for any indication. With the deepening of research, it was discovered
that the antiviral effect of Remdesivir is not limited to filamentous viruses such
as Ebola virus, and it also has inhibitory effects on a variety of viruses such as
coronavirus. The U.S. Food and Drug Administration (FDA) reviewed the
company's application for an investigational new drug (IND) for Remdesivir to
treat Covid-19, and granted investigational new drug authorisation to study the
drug in February 2020.
Remdesivir Mechanism of Action
Remdesivir is a 1'-cyano substituted adenosine nucleotide analogue with
broad-spectrum antiviral activity against a variety of RNA viruses. The
compound has a metabolic mechanism that can activate nucleoside
triphosphate metabolites to inhibit viral RNA polymerase.
COVID-19 is an RNA virus. (RNA is a molecular transcription tool used by
organisms to build proteins using DNA instructions). RNA viruses rely on RNA
polymerase enzyme to grow RNA chain. Remdesivir replaces this polymerase,
which means that RNA cannot develop.
Does Remdesivir Really Work For COVID-19?
During the last Ebola outbreak, there was only one randomized controlled trial
of the drug. As with many trials, the study was stopped before conclusions were
Remdesivir and another trial were discontinued due to a significant increase in
mortality among patients taking Remdesivir, meaning that the drug apparently
did not help those Ebola patients.
Most clinical decisions related to COVID-19 are based on historical epidemics
Ebola, SARS, and MERS. The use of Remdesivir in these three outbreaks has
been very disappointing. So it is hard to make a decision that Remdesivir is
effective against COVID-19.
When Will We Find Out If Remdesivir Is Effective for Treating
As of March 26, 2020:
• There are four U.S. trials.
• Two Chinese trials are expected to be completed in early April.
• There are 2 or 3 European trials that use Remdesivir as a comparator, which
means this is one of the drugs they tested in a multidrug trial.
One Chinese trial was for severe COVID-19 and one was for mild to moderate
• The last day of data collection for severe trial is April 3.
• The last day of moderate to moderate data collection is April 10.
Then, when researchers process data and publish papers through peer review,
there will be a short lag time.
Huateng Pharmaceutical offers Remdesivir key intermediates for sale.
We look forward to drug scientists' research on the synthesis of Remdesivir to
advance their preclinical and clinical research related to the treatment of
COVID-19, so as to promote the control of the epidemic.